LIVE NCPD WEBINARS: July 15 and August 26, 2021

Summer Oncology Nursing Series

A Complimentary NCPD-Accredited Virtual Curriculum

Gynecologic Cancers

Register Now

Register for these complimentary events with the “Register Now ” button above,
which will take you to our Zoom registration page.

All events moderated by
Neil Love, MD
Research To Practice
Miami, Florida

Thursday, July 15, 2021 from 5:00 PM – 6:00 PM Eastern Time

Krishnansu S Tewari, MD
Professor and Division Director
Division of Gynecologic Oncology
University of California, Irvine
Irvine, California
Courtney Arn, CNP
The James Cancer Hospital and Solove Research Institute
The Ohio State University
Columbus, Ohio


Thursday, August 26, 2021 from 5:00 PM – 6:00 PM Eastern Time

Thomas J Herzog, MD
Paul and Carolyn Flory Professor
Deputy Director, University of Cincinnati Cancer Center
Vice-Chair, Quality and Safety
Department of Obstetrics and Gynecology
University of Cincinnati Medical Center
Associate Director, GOG Partners
Cincinnati, Ohio
Kimberly A Spickes, MNSc, RN, APRN, OCN, ACNP-BC
Nurse Practitioner
UAMS Division of Gynecologic Oncology
University of Arkansas for Medical Sciences
Little Rock, Arkansas



These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, GlaxoSmithKline and Merck.

Topics to Be Discussed

  • Overview of the incidences and prognoses of ovarian, endometrial and cervical cancers; patient signs and symptoms at presentation and diagnostic/staging considerations; key patient- and disease-specific factors affecting disease management
  • Clinical strategy for molecular testing for BRCA and other mutations in ovarian cancer; incidence of microsatellite instability (MSI)-high advanced endometrial cancer and PD-L1-positive advanced cervical cancer and current indications for MSI and PD-L1 testing
  • Similarities and differences among the 3 PARP inhibitors FDA approved for ovarian cancer; practical administration of PARP inhibitors as maintenance therapy for patients responding to first-line chemotherapy
  • Spectrum of toxicities associated with various PARP inhibitors and indications for dose modification, delay or interruption
  • Patient and clinical factors in the selection of therapy for metastatic endometrial or cervical cancer in the first-line and recurrent settings; current role and optimal integration of pembrolizumab alone or in combination with lenvatinib in the treatment of recurrent disease
  • Unique supportive care considerations for patients with endometrial or cervical cancer who are receiving therapy with an anti-PD-1 antibody
  • Novel agents and strategies under investigation for advanced gynecologic cancers

Target Audience
These activities have been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gynecologic cancers.

Learning Objectives
Upon completion of each activity, participants should be able to

  • Consider the FDA approvals of olaparib and niraparib as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer (OC), and counsel patients with and without BRCA mutations regarding appropriate treatment recommendations.
  • Recall the FDA approval of olaparib/bevacizumab as maintenance therapy for patients with newly diagnosed advanced OC responding after first-line platinum-based chemotherapy with bevacizumab whose disease is homologous recombination deficiency-positive, to assess the role of this novel strategy in clinical practice.
  • Appreciate the biologic rationale for and available data with combining veliparib with chemotherapy for OC, and consider the clinical and research implications.
  • Compare and contrast the toxicities associated with the various commercially available PARP inhibitors commonly used in the care of patients with OC, and offer supportive management strategies to minimize and ameliorate these side effects.
  • Understand the importance of microsatellite instability (MSI) testing for patients with gynecologic cancers, and identify the benefits observed with anti-PD-1/PD-L1 antibodies for MSI-high or mismatch repair-deficient disease.
  • Recognize the FDA approval of pembrolizumab in combination with lenvatinib for advanced, recurrent endometrial cancer that is not MSI high or mismatch repair deficient in order to identify patients appropriate for this novel approach.
  • Evaluate the efficacy and safety of anti-PD-1 monotherapy for PD-L1-positive recurrent or metastatic cervical cancer that progresses on or after chemotherapy, and use this information to educate patients about the benefits and risks of this approach.
  • Recognize the incidence of tissue factor expression in patients with cervical and other gynecologic cancers, and consider the potential role of novel agents designed to exploit this therapeutic target.
  • Assess the toxicities associated with immune checkpoint inhibitors and other novel agents for gynecologic cancers, and offer patients supportive management strategies to minimize and ameliorate these side effects.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
Each educational activity for 1 contact hour is provided by RTP.

Each activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for each event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Arn and Ms Spickes have no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr HerzogAdvisory Committee: Aravive Inc, AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Gradalis Inc, GlaxoSmithKline, Merck; Data and Safety Monitoring Board/Committee: Corcept Therapeutics, Incyte Corporation. Dr TewariAdvisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Merck, Tesaro, A GSK Company; Contracted Research (to Institution): Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Merck, Tesaro, A GSK Company.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, GlaxoSmithKline and Merck.